|
|
 |
 |
| |
 Printable version |
Radiolabelled therapy in the field of neuroendocrine tumors |
Hépato-Gastro. Volume 16, 43-55, octobre 2009, Mini-revue
|
 Résumé
Article gratuit
|
Author(s) : Sophie Leboulleux, Eric Baudin, Joël Guigay, Michel Ducreux, Martin Schlumberger, Jean Lumbroso |
Summary : Peptide receptor radiolabelled therapy (PRRT) constitues one of the most promising approach in the field of neuroendocrine tumors. Preliminary studies report a 30 % objective response rate in selected patients based on results of somatostatin receptor scintigraphy. Complexity of clinical research hampered a rapid PRRT development in France. Implementation of randomized study allowing predictors of response to be validated is a priority. |
Keywords : radiolabelled therapy, neuroendocrine tumor, predictor of response |
|
